{"url_path":"/sec/afjk/8-k/2026-07-06/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1979005/0001493152-26-032151-index.html","accession_number":"0001493152-26-032151","cik":"0001979005","ticker":"AFJK","issuer_name":"Aimei Health Technology Co., Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1979005/0001493152-26-032151-index.html","primary_entity_key":"0001979005","primary_entity_name":"Aimei Health Technology Co., Ltd."},"word_count":345,"has_tables":true,"body_markdown":"false\n0001979005\n\n0001979005\n\n2026-07-06\n2026-07-06\n\n0001979005\n\nAFJK:OrdinarySharesParValue0.0001PerShareMember\n\n2026-07-06\n2026-07-06\n\n0001979005\n\nAFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember\n\n2026-07-06\n2026-07-06\n\n0001979005\n\nAFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember\n\n2026-07-06\n2026-07-06\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**United\nStates**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**Form\n8-K**\n\n \n\n**Current\nReport**\n\n \n\n**Pursuant\nto Section 13 or 15(d) of the**\n\n**Securities\nExchange Act of 1934**\n\n \n\n**July\n6, 2026**\n\nDate\nof Report (Date of earliest event reported)\n\n \n\n**AIMEI\nHEALTH TECHNOLOGY CO., LTD**\n\n(Exact\nName of Registrant as Specified in its Charter)\n\n \n\n**Cayman\nIslands**\n \n**001-41880**\n \n**N/A 00-0000000**\n\n(State\nor other jurisdiction\n\nof\nincorporation)\n\n \n\n(Commission\n\nFile\nNumber)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**10\nEast 53rd Street, Suite 3001**\n\n**New\nYork, NY**\n\n \n**10022**\n\n(Address of Principal Executive\nOffices)\n \n(Zip Code)\n\n \n\n**86-13758131392**\n\nRegistrant’s\ntelephone number, including area code\n\n \n\n**N/A**\n\n(Former\nname or former address, if changed since last report)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐\nWritten communications\npursuant to Rule 425 under the Securities Act\n\n \n \n\n☐\nSoliciting material pursuant\nto Rule 14a-12 under the Exchange Act\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each Class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nOrdinary\nShares, par value $0.0001 per share\n \nAFJK\n \nThe Nasdaq Stock Market\nLLC\n\nRights,\nexchangeable into one-fifth of one Ordinary Share\n \nAFJKR\n \nThe Nasdaq Stock Market\nLLC\n\nUnits,\neach consisting of one Ordinary Share and one Right\n \nAFJKU\n \nThe Nasdaq Stock Market\nLLC\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}